Xponance, Inc. Taysha Gene Therapies, Inc. Transaction History
Xponance, Inc.
- $12.3 Billion
- Q3 2025
A detailed history of Xponance, Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 16,575 shares of TSHA stock, worth $67,957. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,575
Previous 12,837
29.12%
Holding current value
$67,957
Previous $29,000
79.31%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TSHA
# of Institutions
154Shares Held
246MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$103 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$96.6 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$89 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$69.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$52.7 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $198M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...